JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on December 13, 2002; DOI: 10.1124/jpet.102.044743


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.102.044743v1
304/3/1280    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gadi, V. K.
Right arrow Articles by Sorscher, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gadi, V. K.
Right arrow Articles by Sorscher, E. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cancer Chemotherapy

Vol. 304, Issue 3, 1280-1284, March 2003

A Long-Acting Suicide Gene Toxin, 6-Methylpurine, Inhibits Slow Growing Tumors after a Single Administration

Vijayakrishna K. Gadi , Sherrie D. Alexander, William R. Waud, Paula W. Allan, William B. Parker and Eric J. Sorscher

Department of Medicine (V.K.G., E.J.S.) and Department of Physiology and Biophysics (V.K.G., S.D.A., E.J.S.), University of Alabama at Birmingham, Birmingham, Alabama; Southern Research Institute (W.R.W., P.W.A., W.B.P.), Birmingham, Alabama

We have demonstrated antitumor activity against refractory human glioma and pancreatic tumors with 6-methylpurine (MeP) using either a suicide gene therapy strategy to selectively release 6-methylpurine in tumor cells or direct intratumoral injection of 6-methylpurine itself. A single i.p. injection in mice of the prodrug 9-beta -D-[2-deoxyribofuranosyl]-6-methylpurine (MeP-dR; 134 mg/kg) caused sustained regression lasting over 70 days of D54 (human glioma) tumors transduced with the Escherichia coli purine nucleoside phosphorylase (PNP), and a single intratumoral injection of 6-methylpurine (5-10 mg/kg) elicited prolonged delays of the growth of D54 tumors and CFPAC human pancreatic carcinoma. Because the D54 tumor doubling time is >15 days, the experiments indicate that prodrug activation by E. coli PNP engenders destruction of both dividing and nondividing tumor compartments in vivo and, therefore, address a fundamental barrier that has limited the development of suicide gene strategies in the past. A prolonged retention time of 6-methylpurine metabolites in tumors was noted in vivo (T1/2 >24 h compared with a serum half-life of <1 h). By high-pressure liquid chromatography, metabolites of [3H]MeP-dR were 5- to 6-fold higher in tumors expressing E. coli PNP. These experiments point to new endpoints for monitoring E. coli PNP suicide gene therapy, including intratumoral enzymatic activity, in situ (intratumoral) prodrug conversion, and tumor regressions after direct injection of a suicide gene toxin. The findings also help explain the strong in vivo bystander killing mechanism ascribed by several laboratories to E. coli PNP in the past.


0022-3565/03/3043-1280$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
J.-W. Ting, M.-F. Wu, C.-T. Tsai, C.-C. Lin, I.-C. Guo, and C.-Y. Chang
Identification and characterization of a novel gene of grouper iridovirus encoding a purine nucleoside phosphorylase
J. Gen. Virol., October 1, 2004; 85(10): 2883 - 2892.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. S. Hong, W. R. Waud, D. N. Levasseur, T. M. Townes, H. Wen, S. A. McPherson, B. A. Moore, Z. Bebok, P. W. Allan, J. A. Secrist III, et al.
Excellent In vivo Bystander Activity of Fludarabine Phosphate against Human Glioma Xenografts that Express the Escherichia coli Purine Nucleoside Phosphorylase Gene
Cancer Res., September 15, 2004; 64(18): 6610 - 6615.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.